1-7 of 7
Ricardo M. Attar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

Sheri L. Moores, Mark L. Chiu, Barbara S. Bushey, Kristen Chevalier, Leopoldo Luistro, Keri Dorn, Randall J. Brezski, Peter Haytko, Thomas Kelly, Sheng-Jiun Wu, Pauline L. Martin, Joost Neijssen, Paul W.H.I. Parren, Janine Schuurman, Ricardo M. Attar, Sylvie Laquerre, Matthew V. Lorenzi, G. Mark Anderson
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (13): 3942–3953.
https://doi.org/10.1158/0008-5472.CAN-15-2833
Published: 30 June 2016
View article titled, A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
Open the PDF for A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors in another window
Includes: Supplementary data
Journal Articles

Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer

Ricardo M. Attar, Maria Jure-Kunkel, Aaron Balog, Mary Ellen Cvijic, Janet Dell-John, Cheryl A. Rizzo, Liang Schweizer, Thomas E. Spires, J. Suso Platero, Mary Obermeier, Weifang Shan, Mark E. Salvati, William R. Foster, Joseph Dinchuk, Shen-Jue Chen, Gregory Vite, Robert Kramer, Marco M. Gottardis
Journal: Cancer Research
Cancer Res (2009) 69 (16): 6522–6530.
https://doi.org/10.1158/0008-5472.CAN-09-1111
Published: 12 August 2009
View article titled, Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
Open the PDF for Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

Fei Huang, Ann Greer, Warren Hurlburt, Xia Han, Rameh Hafezi, Gayle M. Wittenberg, Karen Reeves, Jiwen Chen, Douglas Robinson, Aixin Li, Francis Y. Lee, Marco M. Gottardis, Edwin Clark, Lee Helman, Ricardo M. Attar, Ashok Dongre, Joan M. Carboni
Journal: Cancer Research
Cancer Res (2009) 69 (1): 161–170.
https://doi.org/10.1158/0008-5472.CAN-08-0835
Published: 31 December 2008
View article titled, The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
Open the PDF for The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors in another window
Includes: Supplementary data
Journal Articles

Preclinical assessment of gene expression and proteomic profiles promoted by the novel antiandrogen BMS-641988, bicalutamide and castration.

Ricardo M. Attar, Aaron J. Balog, Jing Chen, Shen-Jue Chen, Mark Curran, Mary-Ellen Cvijic, Janet Dell-John, Joseph E. Dinchuk, Gennaro Dito, Ashok R. Dongre, William R. Foster, Aiqing He, Ching-Ping Ho, Donald Jackson, Maria N. Jure-Kunkel, Anne C. Lewin, Cheryl A. Rizzo, Douglas M. Robinson, Mark E. Salvati, Liang Schweizer, Thomas E. Spires, Jr., Gregory D. Vite, Michael Woo, Li-An Xu, Marco Gottardis
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1254.
Published: 15 April 2006
View article titled, Preclinical assessment of gene expression and proteomic profiles promoted by the novel antiandrogen BMS-641988, bicalutamide and castration.
Journal Articles

In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417

Paul Haluska, Joan M. Carboni, David A. Loegering, Francis Y. Lee, Mark Wittman, Mark G. Saulnier, David B. Frennesson, Kimberly R. Kalli, Cheryl A. Conover, Ricardo M. Attar, Scott H. Kaufmann, Marco Gottardis, Charles Erlichman
Journal: Cancer Research
Cancer Res (2006) 66 (1): 362–371.
https://doi.org/10.1158/0008-5472.CAN-05-1107
Published: 05 January 2006
View article titled, <em>In vitro</em> and <em>In vivo</em> Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417
Open the PDF for <em>In vitro</em> and <em>In vivo</em> Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417 in another window
Journal Articles

BMS-554417, an inhibitor of the insulin-like growth factor I receptor and insulin receptor, inhibits proliferation and induces mitochondrial pathway-mediated apoptosis in cancer cell lines

Paul Haluska, Joan M. Carboni, David A. Loegering, Francis Y. Lee, Mark Saulnier, David Frennesson, Ricardo M. Attar, Kimberly R. Kalli, Cheryl A. Conover, Sumithra J. Mandrekar, Scott H. Kaufmann, Marco Gottardis, Charles Erlichman
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1191.
Published: 01 May 2005
View article titled, BMS-554417, an inhibitor of the insulin-like growth factor I receptor and insulin receptor, inhibits proliferation and induces mitochondrial pathway-mediated apoptosis in cancer cell lines
Journal Articles

Development of transgenic mouse lines for the evaluation of the androgen receptor activity in vivo

Ricardo M. Attar, Ching-Ping Ho, Mavis Swerdel, Joseph Dinchuk, Janet Dell, Thomas Spires, Liang Schweizer, Tai-An Lin, Mark Salvati, Aaron Balog, Soren Giese, Dacia Pickering, John T. Hunt, Ronald B. Rowley, David Bol, Jacek Ostrowski, Kasim Mookthtiar, Marco Gottardis
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 447.
Published: 01 April 2004
View article titled, Development of transgenic mouse lines for the evaluation of the androgen receptor activity in vivo